Products for Research Use Only

2',3'-cGAMP

CAT: 0804-HY-100564-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100564-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ) . 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm[1].
CAS Number
1441190-66-4
Product Name Alternative
2'-3'-cyclic GMP-AMP
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Endogenous Metabolite; IFNAR; STING
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/2-3-cgamp.html
Purity
99.95
Solubility
H2O : ≥ 50 mg/mL
Smiles
OC1([H])[C@](OP(O)(OC[C@](O[C@@H](N2C3=NC=NC(N)=C3N=C2)[C@@H]4O)([H])[C@@]4([H])O5)=O)([H])[C@H](N6C(NC(N)=NC7=O)=C7N=C6)O[C@]1([H])COP5(O)=O
Molecular Formula
C20H24N10O13P2
Molecular Weight
674.41
Precautions
H302, H315, H319
References & Citations
[1]Zhang X, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013 Jul 25;51 (2) :226-35.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
ACS Appl Bio Mater. 2024 Oct 21;7 (10) :6768-6779.|Acta Materia Medica . 2023 Jun 17.|Adv Sci (Weinh) . 2024 Dec 11:e2408323.|Bioact Mater. 2024 Sep 6:42:345-365.|Brain Behav Immun. 2026 Jan:131:106176.|Cell Commun Signal. 2023 Sep 28;21 (1) :264.|Genes Dis. 2025 Aug 14.|J Immunol. 2021 Apr 15;206 (8) :1844-1857.|J Virol. 2023 Nov 30;97 (11) :e0127923.|Mol Pain. 2025 May 7:17448069251342240.|Nat Commun. 2025 Jun 3;16 (1) :5140.|Res Sq. 2024 May 30.|SSRN. 2025 Jan 24.|World J Tradit Chin Med. 2025 Oct 28.|ACS Nano. 2025 Feb 25;19 (7) :6758-6770.|Adv Mater. 2024 Mar 24:e2401384.|Adv Sci (Weinh) . 2024 Nov 19:e2407222.|bioRxiv. 2024 Apr 12.|bioRxiv. 2025 Nov 17.|Cancers (Basel) . 2024 Oct 30;16 (21) :3657.|Cell Rep. 2023 Feb 28;42 (3) :112145.|Fundam Res. 2023 May 11;5 (1) :183-191.|Hum Vaccin Immunother. 2025 Dec;21 (1) :2567703.|J Med Chem. 2025 Mar 13;68 (5) :5471-5487.|Neuron. 2023 Jan 18;111 (2) :236-255.e7.|Neuropharmacology. 2025 Mar 19:110426.|Protein Cell. 2022 Apr;13 (4) :281-301.